Clinical trial
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
NCT04142424 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 28, 2019
- Completion date
- November 12, 2021
- Enrollment
- 73 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metabolic disorders, non-alcoholic steatohepatitis